Scott Coleman

Scott Coleman has over 20 years of experience in the pharmaceutical industry. Scott is currently the Senior Vice President of Nonclinical Development at Xilio Therapeutics, Inc. since June 2022. Prior to joining Xilio Therapeutics, they worked at Acceleron Pharma as the Vice President of Nonclinical Development from January 2020 to June 2022. Before that, they held the position of Senior Director of Preclinical Safety Evaluation at Acceleron Pharma from January 2018 to January 2020.

Earlier in their career, Coleman served as the Head of Nonclinical Development at Spero Therapeutics from September 2015 to January 2018. Scott also worked at Merck as the Senior Director of Discovery Toxicology and DMPK from January 2015 to May 2015. Prior to that, they held various roles at Cubist Pharmaceuticals, including Senior Director and Director of Discovery Toxicology and DMPK from 2011 to 2015, as well as Senior Scientist from 2006 to 2008.

Coleman started their career at Millennium Pharmaceuticals, where they worked as a Senior Scientist from 2001 to 2006. Overall, they have a strong background in nonclinical development and toxicology within the pharmaceutical industry.

Scott Coleman obtained their Bachelor of Science (BS) degree in toxicology from Northeastern University, where they studied from 1988 to 1993. Scott then went on to pursue a Doctor of Philosophy (PhD) degree in Toxicology at North Carolina State University, which they completed from 1996 to 2000. Furthermore, there is no specific information regarding the start and end year for their education at UMass Chan Medical School.